Skip to main content
for

Dr. Maha Hussain: Faculty Experts

Not seeing the results that match your search? FILTER BY CATEGORY AND FIELD

Dr. Maha Hussain

Northwestern University Feinberg School of Medicine

Genevieve Teuton Professor of Medicine, Division of Hematology/Oncology, Department of Medicine
Deputy Director, Robert H. Lurie Comprehensive Cancer Center

About

Areas of Focus

  • Clinical care for genitourinary cancers, with a focus on prostate and bladder cancer
  • Precision medicine and new therapeutics
  • Clinical research
  • Teaching and mentorship

Work/Research

  • Clinical research in genitourinary oncology
  • Development of novel therapeutics integrating scientific advances into clinical trials in prostate and bladder cancer
  • Research has contributed to impacting the standards of care for metastatic hormone-sensitive and castration-resistant prostate cancer including new FDA indications

Career

Maha Hussain, MD, FACP, FASCO, is the Genevieve Teuton Professor of Medicine in the Division of Hematology-Oncology, Department of Medicine, and the Deputy Director at the Robert H. Lurie Comprehensive Cancer Center of the Northwestern University Feinberg School of Medicine.

Dr. Hussain received her medical degree from Baghdad University College of Medicine and completed her residency and Hem-Onc fellowship at Wayne State University in Detroit, Michigan. She was a faculty at Wayne State University and worked at the Allen Park VA and Detroit VA for many years.

Dr. Hussain is a practicing oncologist, internationally renowned expert and clinical researcher in genitourinary oncology particularly prostate and bladder cancer. Her research, funded by federal grants and contracts, is focused on the development of novel therapeutics integrating scientific advances into clinical trials and has contributed to significantly impacting the standards of care for patients with metastatic hormone sensitive and castration resistant prostate cancer.

Her clinical research and scientific leadership led to her roles in leadership of several international clinical trials the data from which led to FDA approvals of Enzalutamide in non metastatic castration resistant prostate cancer, Olaparib in metastatic castration resistant prostate cancer with HRR-m and Darolutamide in metastatic hormone sensitive prostate cancer. 

She is also an educator and mentor and have guided the career development of many fellows and young faculty at Wayne State University, the University of Michigan and Northwestern University many of whom have chosen an academic career in GU Oncology.

Prior to joining the Northwestern University faculty Dr. Hussain was a tenured Professor, Departments of Internal Medicine and Urology at the University of Michigan where she served in many scientific and leadership roles at the University of Michigan Comprehensive Cancer Center including Associate Director for Clinical Research and Co-Leader of the Prostate Cancer/Genitourinary Oncology Program, as well as the Associate Chief for Clinical Research in the Division of Hematology/Oncology.

Since joining the American Society of Clinical Oncology in 1990, Dr. Hussain has served on numerous committees and boards, including the Scientific Program, Cancer Education, International Affairs, Clinical Practice Guidelines and Cancer Communications committees. In addition, she served as chair of the Cancer Education Committee (2008-2009), the Genitourinary Cancers Symposium Program Committee (2010-2011) and the Genitourinary Cancers Symposium Steering Committee (2013- 2014) and was Associate Editor for Cancer.Net. She was an elected member of the ASCO Board of Directors (2016-2020). 

At the national level Dr. Hussain has served in a variety of scientific leadership roles including the Chair of the SWOG Advanced Prostate Cancer Subcommittee (1994-2012), member (2009-2014) and Chair (2013-2014) of the Integration Panel of the U.S. Army Medical Research and Materiel Command Prostate Cancer Research Program, and a member (2004-2008) and Chair (2007- 2008) of the U.S. Food and Drug Administration Oncology Drug Advisory Committee. Dr. Hussain has served as a member of the NCI-Cancer Biomarker Study Section and the NCI’s Prostate cancer task force.   She currently serves as an EAB member for 5 NCI-designated cancer centers, Meyer Cancer center of Cornell University and the UCLA Prostate Cancer SPORE. 

At the international level Dr Hussain serves as a Steering Committee member of MOVEMBER Global Collaborative Program in Disease Progression and a Trustee, Member of Board of Prostate Cancer UK.

Dr. Hussain is the author/coauthor of more than 350 scholarly articles and book chapters. She serves/has served on the editorial boards for several national and international specialty journals; She currently serves as the Deputy Editor for Journal of Clinical Investigation.

She has been invited to give hundreds of lectures on her work in the United States and many countries around the world.

Dr. Hussain has received many honors and awards, including the University of Michigan Comprehensive Cancer Center Leadership Award (2007), the University of Michigan Medical School League of Research Excellence (2011), and the 2012 Clinical & Health Services Research Award. She was elected as a Fellow of ASCO in 2010. She has been named for many years in America’s Top Doctors” and “America´s Top Doctors for Cancer and since 2017 she was named Castle Connolly Exceptional Women in Medicine. In 2015 she was named one of OncLive’s Giants of Cancer Care. In 2024 she was named a Top Scholar by ScholarGPS and America's Most Honored Doctors 2024 - Top 1%.